Report of Foreign Issuer (6-k)
May 12 2020 - 5:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 11, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S purchases B shares worth DKK 3,051 million from Novo Holdings A/S under the 2020 share repurchase programme
Bagsværd, Denmark,
11 May 2020 – Novo Nordisk A/S has today entered into an agreement to purchase 7,012,500 B shares of DKK 0.20 to a value
of DKK 3,051 million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’ 2020 share repurchase programme
of up to a total of DKK 17 billion to be executed during a 12- month period beginning 5 February 2020. The transaction price is
DKK 435.05 per share and has been calculated as the three-day volume weighted average market price from 6 May to 11 May 2020 in
the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.
Prior to the sale of B shares, Novo Holdings
A/S’ ownership of Novo Nordisk A/S was 28.6% of the share capital and 76.7% of the votes. Following the transaction, Novo
Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 128,751,500 B shares of DKK 0.20, corresponding to 28.3% of the capital
and 76.6% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement
on 6 May 2020 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s
incentive programmes have resulted in a net transfer from Novo Nordisk of 6,904 B shares in the period from 6 May to 11 May.
With the
transactions stated above, Novo Nordisk A/S owns a total of 14,099,149 B shares of DKK 0.20, corresponding to 0.6% of the
share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 of DKK 0.20 including
treasury shares.
Page 2 of 2
About Novo Holdings A/S
Novo Holdings
A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding and investment company
of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s
assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value.
As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant
ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial
assets. For further information please visit www.novoholdings.dk.
About Novo Nordisk A/S
Novo Nordisk
is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given
us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious
chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 30 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 11, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024